In the western Sweden series, FGL2 was associated with a small GIST size at the time of the diagnosis, the spindle cell‐type morphology, the absence of tumour necrosis, a low mitotic count and a low or intermediate estimated risk of recurrence according to the National Institutes of Health stratification scheme (Table 1). This evidence concerns the gene FGL2 and gastrointestinal stromal tumor.